The global live biotherapeutic products and microbiome CDMO market is experiencing remarkable growth, driven by increasing investments in microbiome-based therapeutics, advancements in biotechnology, and the growing number of clinical trials involving live biotherapeutic products. As pharmaceutical and biotechnology companies increasingly outsource manufacturing to specialized contract development and manufacturing organizations (CDMOs), the market is expected to witness robust expansion over the coming years.

According to the latest market analysis, the global live biotherapeutic products and microbiome CDMO market size was valued at USD 76.12 million in 2025 and is projected to grow from USD 104.91 million in 2026 to USD 1,365.86 million by 2034, registering a CAGR of 37.82% during the forecast period (2026–2034).

Key Highlights

• North America holds the largest share of the global live biotherapeutic products and microbiome CDMO market.
• Asia-Pacific is projected to be the fastest-growing region during the forecast period at a notable CAGR.
• By Service Type, the Process Development segment dominates the global market.
• By Service Type, the Analytical & Quality Control Services segment is anticipated to register the fastest CAGR during the forecast period.
• By Product Type, the Live Biotherapeutic Products (LBPs) segment holds the largest market share.
• By Product Type, the Next-Generation Probiotics segment is expected to witness the fastest growth over the forecast period.
• By End User, Pharmaceutical & Biotechnology Companies account for the largest market share.
• By End User, Emerging Biotech Companies are expected to grow at the fastest CAGR during the forecast period.

Market Dynamics

Driver

The increasing focus on microbiome-based therapeutics is one of the major drivers propelling the growth of the live biotherapeutic products and microbiome CDMO market. Pharmaceutical and biotechnology companies are investing heavily in developing innovative microbiome therapies for gastrointestinal disorders, metabolic diseases, oncology, neurological disorders, and immune-related conditions. As these therapies require specialized manufacturing capabilities, CDMOs with expertise in live microbial production, formulation, and regulatory compliance are witnessing increased demand.

Furthermore, advancements in microbiome research, synthetic biology, and precision medicine have accelerated the development pipeline of live biotherapeutic products. Growing collaborations between biotechnology firms, research organizations, and contract manufacturers are enabling faster commercialization while reducing production complexities and operational costs.

Restraint

Despite promising growth prospects, manufacturing live biotherapeutic products remains technically challenging. Maintaining microbial viability, ensuring product stability, and meeting stringent regulatory requirements require highly specialized facilities and quality management systems. These complexities significantly increase production costs and create barriers for smaller manufacturers.

In addition, the evolving regulatory framework surrounding live biotherapeutic products differs across global markets, creating uncertainty for developers and CDMOs. Compliance with varying manufacturing standards, documentation requirements, and clinical regulations can delay product approvals and commercialization timelines.

Opportunity

The rapid expansion of clinical pipelines focused on microbiome therapeutics presents substantial opportunities for CDMOs worldwide. As the number of microbiome-based drug candidates progresses through clinical development, pharmaceutical companies increasingly seek experienced manufacturing partners capable of providing end-to-end development, process optimization, analytical testing, and commercial-scale production.

Emerging markets also offer attractive growth opportunities due to expanding biotechnology ecosystems, increasing healthcare investments, and supportive government initiatives for advanced biologics manufacturing. The adoption of advanced fermentation technologies, automation, and AI-enabled manufacturing processes is expected to further enhance production efficiency and strengthen the market outlook throughout the forecast period.

Top Market Players

• Lonza
• AGC Biologics
• Cerbios-Pharma SA
• Biose Industrie
• Arranta Bio
• NIZO Food Research
• List Labs
• Bio Elpida
• Quay Pharmaceuticals
• Alcami Corporation

Market Segmentation

By Service Type

• Process Development
• Analytical & Quality Control Services
• Clinical Manufacturing
• Commercial Manufacturing
• Fill-Finish Services

By Product Type

• Live Biotherapeutic Products (LBPs)
• Next-Generation Probiotics
• Fecal Microbiota Products
• Engineered Microbial Therapeutics

By End User

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Emerging Biotech Companies

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

Unlock Full Report Insights and Strategic Analysis: https://straitsresearch.com/report/live-biotherapeutic-products-and-microbiome-cdmo-market

The comprehensive report delivers detailed insights into market size, growth forecasts, competitive landscape, emerging technologies, investment trends, regional analysis, company profiling, regulatory developments, strategic initiatives, and future business opportunities. It enables stakeholders, investors, manufacturers, biotechnology companies, and healthcare organizations to make informed business decisions through extensive qualitative and quantitative market intelligence.

About Us

Straits Research is a leading market research and market intelligence organization, specializing in research, analytics, and advisory services along with providing business insights & market research reports.

Contact Us

Email: sales@straitsresearch.com

Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)